Diabetic Macular Edema - Pipeline Review, H2 2017

Date: July 18, 2017
Pages: 193
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D0CEF24F89EEN
Leaflet:

Download PDF Leaflet

Diabetic Macular Edema - Pipeline Review, H2 2017
Diabetic Macular Edema - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2017, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 18, 6, 1, 21 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Diabetic Macular Edema - Overview
Diabetic Macular Edema - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Macular Edema - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Macular Edema - Companies Involved in Therapeutics Development
Aciont Inc
ActiveSite Pharmaceuticals Inc
Acucela Inc
Aerie Pharmaceuticals Inc
Aerpio Therapeutics Inc
Alcon Laboratories Inc
Allergan Plc
Ampio Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Boehringer Ingelheim GmbH
Cell Medica Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Clearside BioMedical Inc
Coherus BioSciences Inc
EyeGate Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
Formycon AG
Genmab A/S
GlaxoSmithKline Plc
Icon Bioscience Inc
Kala Pharmaceuticals Inc
Kalvista Pharmaceuticals Inc
Kowa Company Ltd
Lupin Ltd
Mabion SA
Ocular Therapeutix Inc
Oculis ehf
Ohr Pharmaceutical Inc
Pfizer Inc
pSivida Corp
Regeneron Pharmaceuticals Inc
SciFluor Life Sciences LLC
Senju Pharmaceutical Co Ltd
Stealth BioTherapeutics Inc
ThromboGenics NV
Verseon Corp
Xbrane Biopharma AB
Diabetic Macular Edema - Drug Profiles
(aflibercept + nesvacumab) - Drug Profile
abicipar pegol - Drug Profile
ACU-6151 - Drug Profile
ACX-107 - Drug Profile
aflibercept biosimilar - Drug Profile
aflibercept biosimilar - Drug Profile
AKB-9778 - Drug Profile
ALG-1001 - Drug Profile
Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile
AR-13154 - Drug Profile
ARP-1536 - Drug Profile
ASPPDC-010 - Drug Profile
BI-1026706 - Drug Profile
Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile
brolucizumab - Drug Profile
bromfenac sodium - Drug Profile
cibinetide - Drug Profile
conbercept - Drug Profile
danazol - Drug Profile
darapladib - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone dipropionate XR - Drug Profile
difluprednate - Drug Profile
Drug for Diabetic Macular Edema - Drug Profile
EBI-031 - Drug Profile
elamipretide - Drug Profile
fluocinolone acetonide SR - Drug Profile
HO-10 - Drug Profile
HPV-19 - Drug Profile
JDE-006 - Drug Profile
KPI-285 - Drug Profile
KVD-001 - Drug Profile
LKA-651 - Drug Profile
NM-108 - Drug Profile
OCX-063 - Drug Profile
OTX-TKI - Drug Profile
PF-655 - Drug Profile
Protein to Inhibit VEGF for Ophthalmology - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
RG-7716 - Drug Profile
ripasudil - Drug Profile
SF-0166 - Drug Profile
Small Molecule for Diabetic Macular Edema - Drug Profile
Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile
Small Molecules to Inhibit Plasma Kallikrein for Diabetic Macular Edema - Drug Profile
squalamine lactate - Drug Profile
teprotumumab - Drug Profile
THR-149 - Drug Profile
THR-317 - Drug Profile
triamcinolone acetonide - Drug Profile
triamcinolone acetonide - Drug Profile
VA-999272 - Drug Profile
Diabetic Macular Edema - Dormant Projects
Diabetic Macular Edema - Discontinued Products
Diabetic Macular Edema - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Diabetic Macular Edema, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Diabetic Macular Edema - Pipeline by Aciont Inc, H2 2017
Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H2 2017
Diabetic Macular Edema - Pipeline by Acucela Inc, H2 2017
Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, H2 2017
Diabetic Macular Edema - Pipeline by Aerpio Therapeutics Inc, H2 2017
Diabetic Macular Edema - Pipeline by Alcon Laboratories Inc, H2 2017
Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2017
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H2 2017
Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H2 2017
Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H2 2017
Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017
Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H2 2017
Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2017
Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H2 2017
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Diabetic Macular Edema - Pipeline by Formycon AG, H2 2017
Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2017
Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, H2 2017
Diabetic Macular Edema - Pipeline by Icon Bioscience Inc, H2 2017
Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals Inc, H2 2017
Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, H2 2017
Diabetic Macular Edema - Pipeline by Kowa Company Ltd, H2 2017
Diabetic Macular Edema - Pipeline by Lupin Ltd, H2 2017
Diabetic Macular Edema - Pipeline by Mabion SA, H2 2017
Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, H2 2017
Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2017
Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H2 2017
Diabetic Macular Edema - Pipeline by Pfizer Inc, H2 2017
Diabetic Macular Edema - Pipeline by pSivida Corp, H2 2017
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H2 2017
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H2 2017
Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H2 2017
Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2017
Diabetic Macular Edema - Pipeline by Verseon Corp, H2 2017
Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2017
Diabetic Macular Edema - Dormant Projects, H2 2017
Diabetic Macular Edema - Dormant Projects, H2 2017 (Contd..1), H2 2017
Diabetic Macular Edema - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Diabetic Macular Edema, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
Skip to top


Macular Edema - Pipeline Review, H2 2017 US$ 2,000.00 Nov, 2017 · 42 pages

Ask Your Question

Diabetic Macular Edema - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: